Remantadine-Belmed tablets 50mg №10×2

Name Remantadine-Belmed tabl. The main active ingredient Rimantadine Release form Tablets Dosage 50 mg Pharmacological action Rimantadine hydrochloride (hereinafter referred to as rimantadine) is effective against various strains of the influenza A virus (especially type 2 A). It is active against tick-borne encephalitis viruses (Central European and Russian spring-summer), which belong to the group of arboviruses of the Flaviviridae family. Rimantadine inhibits viral replication early in the cycle, possibly by interfering with viral envelope formation. Genetic studies have shown that the specific protein of the M2 gene of the virion is important in the antiviral effect of rimantadine against the influenza A virus. In vitro, rimantadine inhibits the replication of all three antigenic subtypes of influenza A virus isolated from humans – H1N1, H2N2 and H3N2. Rimantadine does not affect the immunogenetic properties of the inactivated influenza A vaccine. The correlation between the sensitivity of the influenza A virus to rimantadine in vitro and the clinical efficacy of the drug has not been established. Rimantadine has an antitoxic effect in influenza caused by virus B. It is not effective in other acute respiratory viral infections. Influenza viruses change over time. The occurrence of mutations that increase the resistance of influenza viruses may reduce the effectiveness of Remantadine-Belmed. Other factors (eg, changes in viral virulence) may also reduce the effectiveness of antivirals. Physicians prescribing Remantadin-Belmed should take into account the available information on drug susceptibility of antiviral agents. Indications for use Early treatment and prevention of influenza in adults and children over 7 years of age; prevention of influenza during epidemics in adults. Dosage and administration Take orally after meals with water. Influenza treatment should begin within 24-48 hours of the onset of symptoms. As a therapeutic agent for influenza, Remantadin-Belmed is prescribed according to one of the following schemes: Scheme 1: adults: on the 1st day – 100 mg 3 times a day; on the 2nd and 3rd days – 100 mg 2 times a day; on the 4th and 5th days – 100 mg 1 time per day. On the 1st day of the disease, it is possible to prescribe the drug at a dose of 150 mg 2 times a day or 300 mg per 1 dose. Scheme 2: adults: 100 mg (two 50 mg tablets) 2 times a day for 7 days. Children aged 7 to 10 years are prescribed 50 mg 2 times a day; 11-14 years – 50 mg 3 times a day; course of treatment – 5 days. For the prevention of influenza, Remantadin-Belmed is prescribed 50 mg once a day for 10-15 days. As prescribed by the attending physician, it is possible to increase the dose for adults to 100 mg twice a day. In patients with severely impaired liver function, severely impaired renal function (creatinine clearance from 5 to 29 ml / min) or renal insufficiency (creatinine clearance ? 10 ml / min) and elderly patients, a dose reduction to 100 mg per day is recommended. Due to the possibility of accumulation of metabolites of rimantadine in patients with impaired liver and / or kidney function, side effects should be monitored. Application during pregnancy and lactation Use during pregnancy and lactation is contraindicated (for the period of treatment, breastfeeding should be stopped). Influence on the ability to drive a car and potentially dangerous mechanisms When using Remantadine-Belmed, the possibility of a decrease in the ability to concentrate cannot be ruled out, therefore driving vehicles and other activities that require increased attention and reaction speed are not recommended. Precautions In the treatment of patients with renal and / or hepatic insufficiency, a dose reduction is necessary. When using Remantadin-Belmed, an exacerbation of chronic concomitant diseases is possible. Elderly patients with arterial hypertension have an increased risk of developing intracerebral hemorrhage. In patients with indications of a history of epilepsy and anticonvulsant therapy during treatment with Remantadine-Belmed, the risk of developing an epileptic seizure increases. In such cases, it is recommended to prescribe Remantadin-Belmed at a dose of up to 100 mg / day simultaneously with anticonvulsants. In the event of a seizure, Remantadine-Belmed should be discontinued. The drug should not be used in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Remantadine-Belmed is not a substitute for early influenza vaccination as recommended by national health authorities. Physicians should consider local recommendations when deciding whether to prescribe Remantadine-Belmed for the prevention or treatment of influenza. The effectiveness of the use of Remantadine-Belmed for the prevention of influenza virus A has been proven. Remantadine-Belmed does not completely suppress the development of an immune response to an infectious agent, therefore, individuals who took Remantadine-Belmed may develop an immune response due to a disease or vaccination, which is important during subsequent contact with viruses with a similar antigenic composition. If influenza vaccination is carried out during an influenza epidemic, Remantadin-Belmed can be used on the recommendation of a doctor for the purpose of prophylaxis during the period necessary for the production of antibodies (2-4 weeks). The effectiveness of prescribing Remantadin-Belmed to children for the treatment of influenza has not been finally established. If prescribed within 48 hours from the onset of the disease, Remantadin-Belmed reduces the duration of fever and other flu symptoms. At the discretion of the attending physician, Remantadin-Belmed for the treatment of influenza can be prescribed to children over 7 years of age with concomitant diseases (diabetes mellitus, heart disease, sickle cell anemia, etc.), who are at high risk of developing complications. Interaction with other drugs Enhances the stimulating effect of caffeine. Reduces the effectiveness of antiepileptic drugs. Adsorbents, astringents and enveloping agents reduce the absorption of rimantadine. Means that acidify urine (ammonium chloride, ascorbic acid, etc.) reduce the effectiveness of rimantadine (due to increased excretion by the kidneys). Urine alkalizing agents (acetosalamide, sodium bicarbonate, etc.) increase its effectiveness (due to a decrease in the excretion of rimantadine by the kidneys). Paracetamol and acetylsalicylic acid reduce the maximum plasma concentration of rimantadine by 11%. Cimetidine reduces the clearance of rimantadine by 18%. Intranasal live attenuated influenza vaccine should not be given until 48 hours after stopping Remantadine-Belmed. Remantadine-Belmed is not recommended to be taken within two weeks after the introduction of an intranasal live attenuated vaccine, because. rimantadine may interfere with the replication of the virus strains contained in the vaccine. Contraindications Hypersensitivity to the drug, acute liver disease, acute and chronic kidney disease, thyrotoxicosis, pregnancy and lactation (for the period of treatment should stop breastfeeding), children under 7 years of age. Carefully. Epilepsy, arterial hypertension, cerebral atherosclerosis, chronic renal and / or liver failure. Composition Each tablet contains: active substance: rimantadine hydrochloride – 50 mg; excipients: lactose monohydrate, calcium stearate (E-470), methylcellulose, potato starch. Overdose When using Remantadin-Belmed in high doses, there is an increase in side effects. An overdose of amantadine (a drug similar to rimantadine) was manifested by the development of agitation, hallucinations, cardiac arrhythmias, and a fatal outcome is possible. If symptoms of an overdose occur, stop taking the drug and consult a doctor. Side effects On the part of the central nervous system: decreased ability to concentrate, insomnia, dizziness, headache, nervousness, irritability, excessive fatigue, ataxia, depression, gait disturbances, euphoria, increased motor activity, tremor, hallucinations, convulsions. From the digestive system: dryness of the oral mucosa, anorexia, nausea, gastralgia, vomiting, flatulence, diarrhea. From the respiratory system: dyspnea, bronchospasm, cough. From the senses: tinnitus, impaired or loss of taste, impaired sense of smell. From the side of the cardiovascular system: palpitations, tachycardia, arterial hypertension, cerebrovascular disorders, heart failure, syncope. Other: hyperbilirubinemia, allergic reactions (skin rash). The incidence of adverse reactions, especially those associated with the gastrointestinal tract and the nervous system, increases significantly when taking doses higher than those recommended. In the event of the above adverse reactions or adverse reactions not listed in these instructions for medical use of the drug, you should consult a doctor. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Remantadin-Belmed tablets 50mg No. 10×2